ft 29 jul 93 uk compani news zeneca face struggl beat hostil environ zeneca ici recent float bioscienc busi could born inauspici time pharmaceut agrochem special busi struggl extrem hostil environ healthcar reform germani itali stun european drug market static compar 8 per cent increas last year reform franc uk well addit measur germani expect next 12 month us reform also prepar clinton administr although expand power bulk buyer healthcar probabl impact reform meanwhil zeneca pharmaceut divis struggl us patent expiri best sell drug heart treatment tenormin world fifth top sell drug sale pound 652m us sale halv less 12 month agrochem sector zeneca second largest ciba switzerland struggl higher develop cost direct result greater regul stagnant market reform common agricultur polici knock european market world largest backward special oper also suffer gener recess mr john mayo zeneca financ director architect split ici admit divis result unaccept zeneca import oper pharmaceut divis sale last year pound 1 6bn best way deal new price consciou drug environ would compens innov compound drive growth volum zeneca four product fast expand sale three zoladex nolvadex diprivan hospit product protect worst healthcar reform germani us fourth zestril heart drug must struggl larg number competit product class group work cut differenti product particularli us four product start stagnat 1996 1997 accord kleinwort benson analyst growth depend upon new product antibiot merrem casodex treatment prostat cancer beyond accol asthma treatment seroquel therapi schizophrenia zeneca thoroughli reorganis research develop activ recent year manag maintain equal drug fail develop process like earlier compound statil corwin meantim zeneca manag must show teeth adapt new environ pharmaceut group busi adjust cost base adapt new circumst itali germani us zeneca laid 100 pharmaceut sale repres us addit cut may necessari pharmaceut divis certainli obligatori special busi last year gener oper profit pound 26m sale pound 936m zeneca agrochem busi gener sale last year pound 1 2bn futur secur profit problem competit becom tougher seri merger acquisit creat signific opposit shell busi acquir american cyanamid rhone poulenc franc link sumitomo japan schere berlin base group form joint ventur hoechst germani turn take agrochem busi major own subsidiari roussel uclaf franc immedi futur zeneca agrochem busi may surpris follow use agrochem result report last week monsanto us longer term oper find go ever tougher zeneca manag insist compani suffici larg cope new harsh environ may zeneca nimbl freed deaden hand ici millbank headquart bureaucraci compani must show adapt quickli enough surviv